Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007

Pediatric Blood & Cancer
Dominik SchreyJoachim Boos

Abstract

On a voluntary basis therapeutic drug monitoring (TDM) was implemented in the ALL-BFM 2000 protocol for the three currently used asparaginase (ASNase) preparations (first line: native Escherichia coli ASNase; second line: pegylated ASNase and third line: Erwinia chrysanthemi ASNase). Between 2000 and 2007, 2,074 ASNase samples from 763 patients out of 114 hospitals were evaluated (5,000 U/m2 E. coli ASNase (n = 318), 1,000 U/m2 pegylated ASNase (n = 416) and 10,000 U/m2 Erwinia chrysanthemi ASNase (n = 29)). First-line therapy with 5,000 U/m2 E. coli ASNase resulted in an ASNase activity of <100 U/L in 10% of all samples from day +3 after administration. Second-line treatment with 1,000 U/m2 PEG ASNase led to activity values below 100 U/L in approximately 30% of all samples taken +7 days. Relating ASNase activity to route of administration, 10,000 U/m2 Erwinia ASNase IM compared to IV as third-line treatment, led to a higher median activity (IM: median 151.5 U/L, range (0-750 U/L); IV: median 115 U/L, range (0-884 U/L), P = 0.3) and fewer samples below 100 U/L (IM: 15% vs. IV: 45%) at day +2. The reduced dose of 5,000 U/m2 E. coli ASNase for induction treatment succeeded to achieve an activity level above 100 U/L in more than 9...Continue Reading

References

Feb 1, 1970·Cancer·H F OettgenJ H Burchenal
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L AsselinH J Cohen
Aug 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BoosH Jürgens
Oct 13, 1998·Critical Reviews in Oncology/hematology·H J Müller, J Boos
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H WooM V Relling
Sep 24, 2004·Pediatric Blood & Cancer·Beata Zalewska-SzewczykJerzy Bodalski
Aug 13, 2009·Pediatric Blood & Cancer·Lynda M VroomanLewis B Silverman

❮ Previous
Next ❯

Citations

Jun 25, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Gillian M Keating
Jun 4, 2013·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·C Moscardó GuillemeL Madero López
Feb 22, 2011·Pediatric Blood & Cancer·Dominik SchreyJoachim Boos
Nov 14, 2014·Pediatric Blood & Cancer·Archie BleyerStephen P Hunger
Jan 30, 2015·Critical Reviews in Oncology/hematology·Abhinav ShrivastavaPradeep K Singhal
Mar 7, 2019·Journal of Cancer Research and Clinical Oncology·Alexander KarachunskiyUNKNOWN ALL-MB study group
Mar 29, 2014·Blood·Carmelo Rizzari
Apr 24, 2020·Pediatric Blood & Cancer·John C PanettaMary V Relling
Dec 18, 2013·Therapeutic Drug Monitoring·Claudia Lanvers-KaminskyJoachim Boos
Jan 15, 2015·Leukemia & Lymphoma·Barbara Asselin, Carmelo Rizzari
May 1, 2016·International Journal of Hematologic Oncology·Xavier Thomas, Caroline Le Jeune
Jul 22, 2016·Journal of Pharmacology & Pharmacotherapeutics·Rachel A EglerYousif Matloub
Feb 16, 2017·Cancer Chemotherapy and Pharmacology·Claudia Lanvers-Kaminsky
Oct 19, 2017·Leukemia & Lymphoma·Wanda SalzerBernard Marini
Sep 1, 2018·Translational and Clinical Pharmacology·Hyeon-Cheol JeongKwang-Hee Shin
Feb 13, 2013·Current Opinion in Oncology·Carmelo RizzariMartin Schrappe
Feb 6, 2020·Hematology, Transfusion and Cell Therapy·Ana Paula BattistelMariana Bohns Michalowski

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.